source
- Regeneron explores pairing its obesity drug with lipid-lowering therapy to differentiate in crowded GLP-1 marketThe pipeline of GLP-1 based medicines is delivering increasingly strong weight-loss results, prompting many companies to seek ways to stand out as the market fills. Regeneron said it is looking at…
- Swedish biotech AnaCardio secures $70.9M Series B to advance heart failure drugSwedish biotech AnaCardio announced a Series B financing round that raised €62.5 million ($70.9 million). The capital will be used to move its chronic advanced heart failure drug toward registrati…